Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;14(6):808-16.
doi: 10.1093/neuonc/nos082. Epub 2012 Apr 16.

Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma

Affiliations

Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma

Derek R Johnson et al. Neuro Oncol. 2012 Jun.

Abstract

Cognitive dysfunction is a common manifestation of primary brain tumors. We evaluated the association between early cognitive dysfunction and prognosis in a cohort of patients with newly diagnosed glioblastoma. Ninety-one patients who completed neuropsychological assessment after tumor resection but before further treatment were identified in the MD Anderson Neuropsychology database. The relationship between performance on cognitive testing and survival was evaluated using not only Cox proportional hazards models that included clinical factors such as age and KPS but also the Kaplan-Meier method. Median survival time from surgery was 20.7 months. Rates of impairment on cognitive testing ranged from 7.1% for Similarities, to 60.0% for Hopkins Verbal Learning Test-Revised Total Recall. As continuous variables, the Clinical Trial Battery Composite, Trail Making Test Part B, and Controlled Oral Word Association test were associated with survival. Impairment on the Trail Making Test Part B, Controlled Oral Word Association, Similarities, and Digit Span were associated with mortality. Kaplan-Meier analysis demonstrated the survival impact of these tests on the group as a whole and in select patient subgroups defined by classification by the Radiation Therapy Oncology Group (RTOG) Recursive Partitioning Analysis (RPA). Cognitive impairment as measured by specific neuropsychological tests is independently associated with poor prognosis in patients with newly diagnosed glioblastoma, and this effect remains significant even within patient subgroups defined by RTOG RPA class. Executive function and attention are the cognitive domains most closely associated with prognosis in this analysis.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Kaplan–Meier plot of survival by impairment on (A) COWA, P = .0029; (B) Digit Span, P = .0003; (C) Similarities, P < .0001; and (D) TMTB, P < .0001.
Fig. 2.
Fig. 2.
Kaplan–Meier plots of survival by number of tests in impaired range amongst COWA, Digit Span, Similarities, and TMTB.
Fig. 3.
Fig. 3.
Overall survival, stratified by presence/absence of impairment on cognitive tests in subgroups defined by RTOG RPA class. Comparisons significant at the P ≤ .05 level include 3b (P = .0026), 3c (P = .0073), 3g (P = .0026), 3k (P = .0009), 3l (P = .0103), and 3o (P = .0045).

References

    1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa043330. - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/S1470-2045(09)70025-7. - DOI - PubMed
    1. Li J, Wang M, Won M, et al. Validation and simplification of the Radiation Therapy Oncology Group Recursive Partitioning Analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;81(3):623–630. doi:10.1016/j.ijrobp.2010.06.012. - DOI - PMC - PubMed
    1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi:10.1056/NEJMoa043331. - DOI - PubMed
    1. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743–5750. doi:10.1200/JCO.2009.23.0805. - DOI - PubMed